Search…

AstraZeneca's LYNPARZA approved in China.

06/06/2025

On June 4th, AstraZeneca announced that Iressa has been approved by the China National Medical Products Administration for use as a single drug in the treatment of advanced non-small cell lung cancer in adults who have not progressed after receiving platinum-based chemotherapy.

Latest

2 m ago

The public rift between US President Trump and former US Department of Energy Secretary Musk has caused a sharp contrast in their interactions from the past to now, according to well-known American investment analyst Dan Ivins. This confrontation is putting pressure on Tesla's stock price; on June 5th, Tesla's stock price plummeted more than 14%, causing the market value to evaporate by approximately $150 billion. Liz Miller, head of an American investment advisory company, stated that investors are using stock prices to urge Musk to return to his role as CEO of Tesla.

2 m ago

Experts say investors are calling on Musk to return to his original position through the stock price.

3 m ago

Morgan Stanley strategist Wang Ying said that due to the weakening of the US dollar, the trend of the "American exceptionalism" is weakening, and the increasing willingness of investors to diversify, Chinese stocks will attract more fund inflows in the next 6 to 12 months. Wang Ying said in an interview that the global investors' current position in Chinese stocks is "seriously underweight," which is expected to attract fund inflows, especially in the Hong Kong market and American Depositary Receipts (ADR).

3 m ago

Morgan Stanley strategist: It is expected that more funds will flow into Chinese stocks in the next 6-12 months.

4 m ago

In the first five months, the Export-Import Bank of China injected 460 billion yuan in loans into the foreign trade sector.

See all latest